Clinical Trials
22 trialsNCT07227415 2026-06-04
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
Pfizer
Phase 1/2 Recruiting
NCT05287945 2026-05-22
Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma
Oncorena AB
Phase 1/2 Recruiting
NCT00458536 2026-05-19
Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF
Beth Israel Deaconess Medical Center
Phase 1/2 Completed
NCT02535533 2026-05-06
SLM + Axitinib for Clear Cell RCC
University of Iowa
Phase 1/2 Completed
NCT06239194 2026-05-06
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
ModeX Therapeutics, An OPKO Health Company
Phase 1/2 Recruiting
NCT07551349 2026-04-24
DUAL-NK RCC
Beijing Biotech
Phase 1/2 Recruiting
NCT06362369 2026-04-13
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
7 Hills Pharma, LLC
Phase 1/2 Recruiting
NCT05665361 2026-04-07
Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)
National Institutes of Health Clinical Center (CC)
Phase 1/2 Recruiting
NCT05384821 2026-03-18
MetroWilms
Centre Oscar Lambret
Phase 1/2 Recruiting
NCT05888532 2026-03-17
64Cu-GRIP B in Patients With Advanced Malignancies
University of California, San Francisco
Phase 1/2 Recruiting
NCT05672459 2026-02-25
A Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanced HLA-G-Positive Solid Tumors
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
NCT07410676 2026-02-18
EBNK-ST-001
Essen Biotech
Phase 1/2 Recruiting
NCT05468697 2026-01-23
MK-6482-024
Merck Sharp & Dohme LLC
Phase 1/2 Active not recruiting
NCT05070247 2026-01-22
A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
Takeda
Phase 1/2 Terminated
NCT07292168 2026-01-21
TAGNOT
Kidney Cancer Research Bureau
Phase 1/2 Recruiting
NCT07341737 2026-01-15
SL-28 for Advanced Solid Tumours
Second Life Therapeutics
Phase 1/2 Not yet recruiting
NCT05119335 2025-11-12
A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma
NiKang Therapeutics, Inc.
Phase 1/2 Terminated
NCT00722228 2025-10-02
Autologous and Allogeneic Whole Cell Cancer Vaccine for Metastatic Tumors
Hadassah Medical Organization
Phase 1/2 Recruiting
NCT06245915 2025-09-22
AB-2100, an Integrated Circuit T Cell Therapy in Patients With Recurrent Clear-cell Renal Cell Carcinoma (ccRCC)
Arsenal Biosciences, Inc.
Phase 1/2 Active not recruiting
NCT06682793 2025-09-09
DENALI-1
A2 Biotherapeutics Inc.
Phase 1/2 Recruiting
NCT06361810 2025-08-19
PSMA Therapy and Immunotherapy in Kidney Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Withdrawn
NCT05864144 2025-08-15
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Sensei Biotherapeutics, Inc.
Phase 1/2 Active not recruiting